Ryzneuta is a medicine that stimulates the production of white blood cells. It is used to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients receiving cytotoxic chemotherapy (medicines to treat cancer by killing cells). Ryzneuta is not intended for use in patients with chronic myeloid leukaemia or myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced). Ryzneuta contains the active substance efbemalenograstim alfa.
Therapeutic Indication
### Therapeutic indication Ryzneuta is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Therapeutic Area (MeSH)
N/AATC Code
L03AA18
ATC Item
efbemalenograstim alfa
Pharmacotherapeutic Group
Immunostimulants
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| efbemalenograstim alfa | N/A | 艾贝格司亭 |
EMA Name
Ryzneuta
Medicine Name
Ryzneuta
Aliases
N/A